<DOC>
	<DOCNO>NCT03034057</DOCNO>
	<brief_summary>A one-year evaluation Sayana Press self injection woman reproductive age United Kingdom ( UK ) .</brief_summary>
	<brief_title>Sayana Press UK Self-Injection Study</brief_title>
	<detailed_description />
	<criteria>woman age 18 45 year age willing attempt Sayana Press selfinjection home ; woman likely successful DMPA selfinjection program , base opinion investigator ; plan move area least 12 month ; willing contacted clinical staff work home ; evidence personally sign date Informed Consent Document ( ICD ) indicate subject inform pertinent aspect study ; subject willing able comply schedule visit , treatment plan study procedure preexist medical condition would interfere participation study pose risk subject , include hypersensitivity MPA constituent Sayana Press ; know suspected malignancy genital organ ; know suspected malignancy breast ; history cerebrovascular disease metabolic bone disease contraindication DMPA ( UK Medical Eligibility Criteria Category 3 4 ) : Multiple risk factor cardiovascular disease ( e.g . old age , smoking , diabetes , obesity , hypertension ) current history ischaemic heart disease ; stroke ( history cerebrovascular accident , include transient ischaemic attack ) ; unexplained vaginal bleeding ; current history breast cancer ; diabetic nephropathy , neuropathy , retinopathy diabetic vascular disease ; severe ( decompensated ) liver cirrhosis ; hepatocellular adenoma ; hepatoma ; Systemic Lupus Erythematosus ( positive unknown antiphospholipid antibody ; severe thrombocytopenia ; subject investigational centre staff member directly involved conduct study family member , centre staff member otherwise supervised investigator , subject Pfizer employee involve conduct study ; participation study involve investigational drug ( ) within 30 day prior study entry and/or study participation ; patient plan get pregnant within two year study ; breastfeed pregnant subject ; severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgement investigator , would make subject inappropriate entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>